NRAS and hepatocellular carcinoma: Based on the above results, DNA methyltransferase inhibitors can inhibit the activity of DNA methyltransferase, alleviate the inhibition based on methylation, reverse abnormal DNA hypermethylation, affect the expression of NRAS-AS, and then affect the expression of NRAS and inhibit the occurrence and development of HCC.